Cargando…

Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma

The discovery of artemisinin (ART) for malaria treatment won the 2015 Nobel Prize in Medicine, which inspired the rediscovery and development of ART for the treatment of other diseases including cancer. In this study, we investigated the potential therapeutic effect of ART and dihydroartemisinin (DH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Ying, Li, Rui, Zhu, Yuqi, Zhong, Sixia, Qian, Jinjun, Yang, Dongqing, Jurczyszyn, Artur, Beksac, Meral, Gu, Chunyan, Yang, Ye
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242728/ https://www.ncbi.nlm.nih.gov/pubmed/32500030 http://dx.doi.org/10.3389/fonc.2020.00767

Ejemplares similares

Corrigendum: Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma
por: Chen, Ying, et al.
Publicado: (2021)

Suppression of steroid 5α-reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myeloma
por: Dou, Renjie, et al.
Publicado: (2021)

Targeting MK2 Is a Novel Approach to Interfere in Multiple Myeloma
por: Guo, Mengjie, et al.
Publicado: (2019)

Acupuncture Synergized With Bortezomib Improves Survival of Multiple Myeloma Mice via Decreasing Metabolic Ornithine
por: Ke, Mengying, et al.
Publicado: (2021)

HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA
por: Jiang, Fengjie, et al.
Publicado: (2021)

CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma
por: Gu, Chunyan, et al.
Publicado: (2021)

Modified Pulsatillae decoction inhibits DSS-induced ulcerative colitis in vitro and in vivo via IL-6/STAT3 pathway
por: Huangfu, Shaohua, et al.
Publicado: (2020)

Bioactive Compounds from Abelmoschus manihot L. Alleviate the Progression of Multiple Myeloma in Mouse Model and Improve Bone Marrow Microenvironment
por: Hou, Jianhao, et al.
Publicado: (2020)

Extramedullary disease in multiple myeloma: a systematic literature review
por: Bladé, Joan, et al.
Publicado: (2022)

Novel myeloma patient-derived xenograft models unveil the potency of anlotinib to overcome bortezomib resistance
por: Yue, Yanhua, et al.
Publicado: (2022)

Is Quantification of Measurable Clonal Plasma Cells in Stem Cell Grafts (gMRD) Clinically Meaningful?
por: Cengiz Seval, Guldane, et al.
Publicado: (2022)

G6PD promotes cell proliferation and dexamethasone resistance in multiple myeloma via increasing anti-oxidant production and activating Wnt/β-catenin pathway
por: Li, Rui, et al.
Publicado: (2022)

Steroid 5α-Reductase Type I Induces Cell Viability and Migration via Nuclear Factor-κB/Vascular Endothelial Growth Factor Signaling Pathway in Colorectal Cancer
por: Wei, Rongfang, et al.
Publicado: (2020)

Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma
por: Hulin, Cyrille, et al.
Publicado: (2021)

Rational Targeting of Cdc42 Overcomes Drug Resistance of Multiple Myeloma
por: Nguyen, Phuong, et al.
Publicado: (2019)

Drug Targeting of Genomic Instability in Multiple Myeloma
por: Beksac, Meral, et al.
Publicado: (2020)

Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network
por: Antonioli, Elisabetta, et al.
Publicado: (2023)

Dihydroartemisinin: A Potential Drug for the Treatment of Malignancies and Inflammatory Diseases
por: Yu, Ran, et al.
Publicado: (2021)

Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment
por: van der Schans, Jort J., et al.
Publicado: (2020)

Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone
por: Erath, Alexandra, et al.
Publicado: (2020)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
por: Rosiñol, Laura, et al.
Publicado: (2023)

Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma
por: Dolph, Michael, et al.
Publicado: (2021)

Dihydroartemisinin is a Hypoxia-Active Anti-Cancer Drug in Colorectal Carcinoma Cells
por: Ontikatze, Teona, et al.
Publicado: (2014)

Impact of ixazomib‐lenalidomide‐dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging‐markets subgroup of the TOURMALINE‐MM1 trial
por: Spencer, Andrew, et al.
Publicado: (2022)

Dihydroartemisinin Suppresses the Tumorigenesis and Cycle Progression of Colorectal Cancer by Targeting CDK1/CCNB1/PLK1 Signaling
por: Yi, You-Cai, et al.
Publicado: (2021)

Autophagy-dependent cell cycle arrest in esophageal cancer cells exposed to dihydroartemisinin
por: Ma, Qiang, et al.
Publicado: (2020)

Successful Treatment of Concurrently Diagnosed Multiple Myeloma and Myelodysplastic Syndrome With Isolated Del(5q) With Lenalidomide, Bortezomib, and Dexamethasone
por: Washington, Nyomi R, et al.
Publicado: (2021)

Pomalidomide and Dexamethasone Are Effective in Relapsed or Refractory Multiple Myeloma in a Real-Life Setting: A Multicenter Retrospective Study in Taiwan
por: Hung, Yu-Chin, et al.
Publicado: (2021)

First Experience of (11)C-Methionine PET in Multiple Myeloma in Turkey
por: Özkan, Elgin, et al.
Publicado: (2022)

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
por: Spencer, Andrew, et al.
Publicado: (2018)

P872: EFFICACY OF DARATUMUMAB PLUS BORTEZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA PRESENTING WITH EXTRAMEDULLARY DISEASE: A EUROPEAN MYELOMA NETWORK STUDY (EMN19)
por: Beksac, Meral, et al.
Publicado: (2023)

Myeloma as a Second Malignancy following AML: Is a Second Allo Equivalent to Auto?
por: Bakanay, Sule Mine, et al.
Publicado: (2012)

NAT10 acetylates BCL-XL mRNA to promote the proliferation of multiple myeloma cells through PI3K-AKT pathway
por: Zhang, Yuanjiao, et al.
Publicado: (2022)

Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma
por: Gao, Yixing, et al.
Publicado: (2019)

A Rare Extramedullary Presentation of Multiple Myeloma: Paraspinal Muscle Involvement Revealed by FDG PET/CT
por: Özkan, Elgin, et al.
Publicado: (2021)

Heme-Dependent ER Stress Apoptosis: A Mechanism for the Selective Toxicity of the Dihydroartemisinin, NSC735847, in Colorectal Cancer Cells
por: Elhassanny, Ahmed E. M., et al.
Publicado: (2020)

Corrigendum: Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma
por: Gao, Yixing, et al.
Publicado: (2020)

Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib
por: Ataca Atilla, Pınar, et al.
Publicado: (2019)

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
por: Schjesvold, Fredrik, et al.
Publicado: (2021)

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
por: Schjesvold, Fredrik, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9scfkcmj574ctm84pm3515lt99